Top

Molecular Autism

Published in:

Open Access 01-12-2013 | Research

Decitabine alters the expression of Mecp2 isoforms via dynamic DNA methylation at the Mecp2 regulatory elements in neural stem cells

Authors: Vichithra RB Liyanage, Robby M Zachariah, Mojgan Rastegar

Published in: Molecular Autism | Issue 1/2013

Abstract

Background

Aberrant MeCP2 expression in brain is associated with neurodevelopmental disorders including autism. In the brain of stressed mouse and autistic human patients, reduced MeCP2 expression is correlated with Mecp2/MECP2 promoter hypermethylation. Altered expression of MeCP2 isoforms (MeCP2E1 and MeCP2E2) is associated with neurological disorders, highlighting the importance of proper regulation of both isoforms. While known regulatory elements (REs) within the MECP2/Mecp2 promoter and intron 1 are involved in MECP2/Mecp2 regulation, Mecp2 isoform-specific regulatory mechanisms are unknown. We hypothesized that DNA methylation at these REs may impact the expression of Mecp2 isoforms.

Methods

We used a previously characterized in vitro differentiating neural stem cell (NSC) system to investigate the interplay between Mecp2 isoform-specific expression and DNA methylation at the Mecp2 REs. We studied altered expression of Mecp2 isoforms, affected by global DNA demethylation and remethylation, induced by exposure and withdrawal of decitabine (5-Aza-2′-deoxycytidine). Further, we performed correlation analysis between DNA methylation at the Mecp2 REs and the expression of Mecp2 isoforms after decitabine exposure and withdrawal.

Results

At different stages of NSC differentiation, Mecp2 isoforms showed reciprocal expression patterns associated with minor, but significant changes in DNA methylation at the Mecp2 REs. Decitabine treatment induced Mecp2e1/MeCP2E1 (but not Mecp2e2) expression at day (D) 2, associated with DNA demethylation at the Mecp2 REs. In contrast, decitabine withdrawal downregulated both Mecp2 isoforms to different extents at D8, without affecting DNA methylation at the Mecp2 REs. NSC cell fate commitment was minimally affected by decitabine under tested conditions. Expression of both isoforms negatively correlated with methylation at specific regions of the Mecp2 promoter, both at D2 and D8. The correlation between intron 1 methylation and Mecp2e1 (but not Mecp2e2) varied depending on the stage of NSC differentiation (D2: negative; D8: positive).

Conclusions

Our results show the correlation between the expression of Mecp2 isoforms and DNA methylation in differentiating NSC, providing insights on the potential role of DNA methylation at the Mecp2 REs in Mecp2 isoform-specific expression. The ability of decitabine to induce Mecp2e1/MeCP2E1, but not Mecp2e2 suggests differential sensitivity of Mecp2 isoforms to decitabine and is important for future drug therapies for autism.

Available only for authorised users

Zachariah RM, Rastegar M: Linking epigenetics to human disease and Rett syndrome: the emerging novel and challenging concepts in MeCP2 research. Neural plast. 2012, 2012: 415825-PubMedCentralPubMed

Nagarajan RP, Hogart AR, Gwye Y, Martin MR, LaSalle JM: Reduced MeCP2 expression is frequent in autism frontal cortex and correlates with aberrant MECP2 promoter methylation. Epigenetics. 2006, 1: e1-e11. 10.4161/epi.1.1.2642.PubMedCentralCrossRefPubMed

Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY: Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet. 1999, 23: 185-188. 10.1038/13810.CrossRefPubMed

Kriaucionis S, Bird A: The major form of MeCP2 has a novel N-terminus generated by alternative splicing. Nucleic Acids Res. 2004, 32: 1818-1823. 10.1093/nar/gkh349.PubMedCentralCrossRefPubMed

Mnatzakanian GN, Lohi H, Munteanu I, Alfred SE, Yamada T, MacLeod PJ, Jones JR, Scherer SW, Schanen NC, Friez MJ, Vincent JB, Minassian BA: A previously unidentified MECP2 open reading frame defines a new protein isoform relevant to Rett syndrome. Nat Genet. 2004, 36: 339-341. 10.1038/ng1327.CrossRefPubMed

Dragich JM, Kim YH, Arnold AP, Schanen NC: Differential distribution of the MeCP2 splices variants in the postnatal mouse brain. J Comp Neurol. 2007, 501: 526-542. 10.1002/cne.21264.CrossRefPubMed

Zachariah RM, Olson CO, Ezeonwuka C, Rastegar M: Novel MeCP2 isoform-specific antibody reveals the endogenous MeCP2E1 expression in murine brain, primary neurons and astrocytes. PloS one. 2012, 7: e49763-10.1371/journal.pone.0049763.PubMedCentralCrossRefPubMed

Saunders CJ, Minassian BE, Chow EW, Zhao W, Vincent JB: Novel exon 1 mutations in MECP2 implicate isoform MeCP2_e1 in classical Rett syndrome. Am J Med Genet Part A. 2009, 149A: 1019-1023. 10.1002/ajmg.a.32776.CrossRefPubMed

Fichou Y, Nectoux J, Bahi-Buisson N, Rosas-Vargas H, Girard B, Chelly J, Bienvenu T: The first missense mutation causing Rett syndrome specifically affecting the MeCP2_e1 isoform. Neurogenet. 2009, 10: 127-133. 10.1007/s10048-008-0161-1.CrossRef

10.

Dastidar SG, Bardai FH, Ma C, Price V, Rawat V, Verma P, Narayanan V, D’Mello SR: Isoform-specific toxicity of Mecp2 in postmitotic neurons: suppression of neurotoxicity by FoxG1. J Neurosci. 2012, 32: 2846-2855. 10.1523/JNEUROSCI.5841-11.2012.PubMedCentralCrossRefPubMed

11.

Williamson SL, Christodoulou J: Rett syndrome: new clinical and molecular insights. Eur J Hum Genet. 2006, 14: 896-903. 10.1038/sj.ejhg.5201580.CrossRefPubMed

12.

Liu J, Francke U: Identification of cis-regulatory elements for MECP2 expression. Hum Mol Genet. 2006, 15: 1769-1782. 10.1093/hmg/ddl099.CrossRefPubMed

13.

Adachi M, Keefer EW, Jones FS: A segment of the Mecp2 promoter is sufficient to drive expression in neurons. Hum Mol Genet. 2005, 14: 3709-3722. 10.1093/hmg/ddi402.CrossRefPubMed

14.

Jugloff DG, Vandamme K, Logan R, Visanji NP, Brotchie JM, Eubanks JH: Targeted delivery of an Mecp2 transgene to forebrain neurons improves the behavior of female Mecp2-deficient mice. Hum Mol Genet. 2008, 17: 1386-1396. 10.1093/hmg/ddn026.CrossRefPubMed

15.

Kerr B, Soto CJ, Saez M, Abrams A, Walz K, Young JI: Transgenic complementation of MeCP2 deficiency: phenotypic rescue of Mecp2-null mice by isoform-specific transgenes. Eur J Hum Genet. 2012, 20: 69-76. 10.1038/ejhg.2011.145.PubMedCentralCrossRefPubMed

16.

Collins AL, Levenson JM, Vilaythong AP, Richman R, Armstrong DL, Noebels JL, David Sweatt J, Zoghbi HY: Mild overexpression of MeCP2 causes a progressive neurological disorder in mice. Hum Mol Genet. 2004, 13: 2679-2689. 10.1093/hmg/ddh282.CrossRefPubMed

17.

Luikenhuis S, Giacometti E, Beard CF, Jaenisch R: Expression of MeCP2 in postmitotic neurons rescues Rett syndrome in mice. Proc Nat Acad Sci USA. 2004, 101: 6033-6038. 10.1073/pnas.0401626101.PubMedCentralCrossRefPubMed

18.

Singh J, Saxena A, Christodoulou J, Ravine D: MECP2 genomic structure and function: insights from ENCODE. Nucleic Acids Res. 2008, 36: 6035-6047. 10.1093/nar/gkn591.PubMedCentralCrossRefPubMed

19.

Nagarajan RP, Patzel KA, Martin M, Yasui DH, Swanberg SE, Hertz-Picciotto I, Hansen RL, Van de Water J, Pessah IN, Jiang R, Robinson WP, LaSalle JM: MECP2 promoter methylation and X chromosome inactivation in autism. Autism Res. 2008, 1: 169-178. 10.1002/aur.24.PubMedCentralCrossRefPubMed

20.

Franklin TB, Russig H, Weiss IC, Graff J, Linder N, Michalon A, Vizi S, Mansuy IM: Epigenetic transmission of the impact of early stress across generations. Biol Psych. 2010, 68: 408-415.CrossRef

21.

Delcuve GP, Rastegar M, Davie JR: Epigenetic control. J Cell Phys. 2009, 219: 243-250. 10.1002/jcp.21678.CrossRef

22.

Liyanage VRB, Zachariah RM, Delcuve GP, Davie JR, Rastegar M: New Developments in Chromatin Research: An Epigenetic Perspective. New Developments in Chromatin Research. Edited by: Simpson NM, Stewart VJ. 2012, NY, USA: Nova Science Publishers, 29-58.

23.

Jeltsch A: Beyond Watson and Crick: DNA methylation and molecular enzymology of DNA methyltransferases. Chembiochem. 2002, 3: 274-293. 10.1002/1439-7633(20020402)3:4<274::AID-CBIC274>3.0.CO;2-S.CrossRefPubMed

24.

Kriaucionis S, Heintz N: The nuclear DNA base 5-hydroxymethylcytosine is present in Purkinje neurons and the brain. Science. 2009, 324: 929-930. 10.1126/science.1169786.PubMedCentralCrossRefPubMed

25.

Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, Brudno Y, Agarwal S, Iyer LM, Liu DR, Aravind L, Rao A: Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science. 2009, 324: 930-935. 10.1126/science.1170116.PubMedCentralCrossRefPubMed

26.

Elango N, Yi SV: DNA methylation and structural and functional bimodality of vertebrate promoters. Mol Biol Evol. 2008, 25: 1602-1608. 10.1093/molbev/msn110.CrossRefPubMed

27.

Flores K, Wolschin F, Corneveaux JJ, Allen AN, Huentelman MJ, Amdam GV: Genome-wide association between DNA methylation and alternative splicing in an invertebrate. BMC genomics. 2012, 13: 480-10.1186/1471-2164-13-480.PubMedCentralCrossRefPubMed

28.

Shukla S, Kavak E, Gregory M, Imashimizu M, Shutinoski B, Kashlev M, Oberdoerffer P, Sandberg R, Oberdoerffer S: CTCF-promoted RNA polymerase II pausing links DNA methylation to splicing. Nature. 2011, 479: 74-79. 10.1038/nature10442.CrossRefPubMed

29.

Mossman D, Kim KT, Scott RJ: Demethylation by 5-aza-2′-deoxycytidine in colorectal cancer cells targets genomic DNA whilst promoter CpG island methylation persists. BMC cancer. 2010, 10: 366-10.1186/1471-2407-10-366.PubMedCentralCrossRefPubMed

30.

Ishimaru N, Fukuchi M, Hirai A, Chiba Y, Tamura T, Takahashi N, Tabuchi A, Tsuda M, Shiraishi M: Differential epigenetic regulation of BDNF and NT-3 genes by trichostatin A and 5-aza-2′-deoxycytidine in Neuro-2a cells. Biochem Biophys Res Comm. 2010, 394: 173-177. 10.1016/j.bbrc.2010.02.139.CrossRefPubMed

31.

Bazan E, Alonso FJ, Redondo C, Lopez-Toledano MA, Alfaro JM, Reimers D, Herranz AS, Paino CL, Serrano AB, Cobacho N, Caso E, Lobo MV: In vitro and in vivo characterization of neural stem cells. Histol Histopathol. 2004, 19: 1261-1275.PubMed

32.

Tropepe V, Sibilia M, Ciruna BG, Rossant J, Wagner EF, van der Kooy D: Distinct neural stem cells proliferate in response to EGF and FGF in the developing mouse telencephalon. Dev Biol. 1999, 208: 166-188. 10.1006/dbio.1998.9192.CrossRefPubMed

33.

Bartl J, Mori T, Riederer P, Ozawa H, Grunblatt E: Methylphenidate enhances neural stem cell differentiation. J Mol Psych. 2013, 1: 5-10.1186/2049-9256-1-5.CrossRef

34.

Kishi N, Macklis JD: MECP2 is progressively expressed in post-migratory neurons and is involved in neuronal maturation rather than cell fate decisions. Mol Cell Neurosci. 2004, 27: 306-321. 10.1016/j.mcn.2004.07.006.CrossRefPubMed

35.

Rastegar M, Hotta A, Pasceri P, Makarem M, Cheung AY, Elliott S, Park KJ, Adachi M, Jones FS, Clarke ID, Dirks P, Ellis J: MECP2 isoform-specific vectors with regulated expression for Rett syndrome gene therapy. PloS one. 2009, 4: e6810-10.1371/journal.pone.0006810.PubMedCentralCrossRefPubMed

36.

Olynik BM, Rastegar M: The genetic and epigenetic journey of embryonic stem cells into mature neural cells. Frontiers in genetics. 2012, 3: 81-PubMedCentralCrossRefPubMed

37.

Barber BA, Liyanage VR, Zachariah RM, Olson CO, Bailey MA: Dynamic expression of MEIS1 homeoprotein in E14.5 forebrain and differentiated forebrain-derived neural stem cells. Ann Anat. 2013, 195: 431-440. 10.1016/j.aanat.2013.04.005.CrossRefPubMed

38.

Lambert JF, Benoit BO, Colvin GA, Carlson J, Delville Y, Quesenberry PJ: Quick sex determination of mouse fetuses. J Neurosci Methods. 2000, 95: 127-132. 10.1016/S0165-0270(99)00157-0.CrossRefPubMed

39.

Hartshorn C, Rice JE, Wangh LJ: Developmentally-regulated changes of Xist RNA levels in single preimplantation mouse embryos, as revealed by quantitative real-time PCR. Mol Reprod Dev. 2002, 61: 425-436. 10.1002/mrd.10037.CrossRefPubMed

40.

Kobrossy L, Rastegar M, Featherstone M: Interplay between chromatin and trans-acting factors regulating the Hoxd4 promoter during neural differentiation. J Biol Chem. 2006, 281: 25926-25939. 10.1074/jbc.M602555200.CrossRefPubMed

41.

Nolte C, Rastegar M, Amores A, Bouchard M, Grote D, Maas R, Kovacs EN, Postlethwait J, Rambaldi I, Rowan S, Yan YL, Zhang F, Featherstone M: Stereospecificity and PAX6 function direct Hoxd4 neural enhancer activity along the antero-posterior axis. Dev Biol. 2006, 299: 582-593. 10.1016/j.ydbio.2006.08.061.CrossRefPubMed

42.

Huang H, Rastegar M, Bodner C, Goh SL, Rambaldi I, Featherstone M: MEIS C termini harbor transcriptional activation domains that respond to cell signaling. J Biol Chem. 2005, 280: 10119-10127. 10.1074/jbc.M413963200.CrossRefPubMed

43.

Rastegar M, Kobrossy L, Kovacs EN, Rambaldi I, Featherstone M: Sequential histone modifications at Hoxd4 regulatory regions distinguish anterior from posterior embryonic compartments. Mol Cel Biol. 2004, 24: 8090-8103. 10.1128/MCB.24.18.8090-8103.2004.CrossRef

44.

Manczak M, Mao P, Nakamura K, Bebbington C, Park B, Reddy PH: Neutralization of granulocyte macrophage colony-stimulating factor decreases amyloid beta 1–42 and suppresses microglial activity in a transgenic mouse model of Alzheimer’s disease. Hum Mol Genet. 2009, 18: 3876-3893. 10.1093/hmg/ddp331.PubMedCentralCrossRefPubMed

45.

Tsoporis JN, Marks A, Haddad A, Dawood F, Liu PP, Parker TG: S100B expression modulates left ventricular remodeling after myocardial infarction in mice. Circulation. 2005, 111: 598-606. 10.1161/01.CIR.0000154554.65287.F5.CrossRefPubMed

46.

Schneider L, d’Adda di Fagagna F: Neural stem cells exposed to BrdU lose their global DNA methylation and undergo astrocytic differentiation. Nucleic Acids Res. 2012, 40: 5332-5342. 10.1093/nar/gks207.PubMedCentralCrossRefPubMed

47.

Mack JT, Beljanski V, Soulika AM, Townsend DM, Brown CB, Davis W, Tew KD: “Skittish” Abca2 knockout mice display tremor, hyperactivity, and abnormal myelin ultrastructure in the central nervous system. Mol Cell Biol. 2007, 27: 44-53. 10.1128/MCB.01824-06.PubMedCentralCrossRefPubMed

48.

Ghoshal K, Datta J, Majumder S, Bai S, Kutay H, Motiwala T, Jacob ST: 5-Aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signal. Mol Cell Biol. 2005, 25: 4727-4741. 10.1128/MCB.25.11.4727-4741.2005.PubMedCentralCrossRefPubMed

49.

Rastegar M, Rousseau GG, Lemaigre FP: CCAAT/enhancer-binding protein-alpha is a component of the growth hormone-regulated network of liver transcription factors. Endocrinol. 2000, 141: 1686-1692.

50.

Wu CH, Rastegar M, Gordon J, Safa AR: Beta(2)-microglobulin induces apoptosis in HL-60 human leukemia cell line and its multidrug resistant variants overexpressing MRP1 but lacking Bax or overexpressing P-glycoprotein. Oncogene. 2001, 20: 7006-7020. 10.1038/sj.onc.1204893.CrossRefPubMed

51.

Gordon J, Wu CH, Rastegar M, Safa AR: Beta2-microglobulin induces caspase-dependent apoptosis in the CCRF-HSB-2 human leukemia cell line independently of the caspase-3, -8 and -9 pathways but through increased reactive oxygen species. Int J Cancer. 2003, 103: 316-327. 10.1002/ijc.10828.CrossRefPubMed

52.

Ko M, Huang Y, Jankowska AM, Pape UJ, Tahiliani M, Bandukwala HS, An J, Lamperti ED, Koh KP, Ganetzky R, Liu XS, Aravind L, Agarwal S, Maciejewski JP, Rao A: Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature. 2010, 468: 839-843. 10.1038/nature09586.PubMedCentralCrossRefPubMed

53.

Choufani S, Shapiro JS, Susiarjo M, Butcher DT, Grafodatskaya D, Lou Y, Ferreira JC, Pinto D, Scherer SW, Shaffer LG, Coullin P, Caniggia I, Beyene J, Slim R, Bartolomei MS, Weksberg R: A novel approach identifies new differentially methylated regions (DMRs) associated with imprinted genes. Genome Res. 2011, 21: 465-476. 10.1101/gr.111922.110.PubMedCentralCrossRefPubMed

54.

Nandakumar V, Vaid M, Katiyar SK: (-)-Epigallocatechin-3-gallate reactivates silenced tumor suppressor genes, Cip1/p21 and p16INK4a, by reducing DNA methylation and increasing histones acetylation in human skin cancer cells. Carcinogen. 2011, 32: 537-544. 10.1093/carcin/bgq285.CrossRef

55.

Liu Q, Yang L, Gong C, Tao G, Huang H, Liu J, Zhang H, Wu D, Xia B, Hu G, Wang K, Zhuang Z: Effects of long-term low-dose formaldehyde exposure on global genomic hypomethylation in 16HBE cells. Toxicol Lett. 2011, 205: 235-240. 10.1016/j.toxlet.2011.05.1039.CrossRefPubMed

56.

Christman JK: 5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene. 2002, 21: 5483-5495. 10.1038/sj.onc.1205699.CrossRefPubMed

57.

Squillaro T, Alessio N, Cipollaro M, Melone MA, Hayek G, Renieri A, Giordano A, Galderisi U: Reduced expression of MECP2 affects cell commitment and maintenance in neurons by triggering senescence: new perspective for Rett syndrome. Mol Biol Cell. 2012, 23: 1435-1445. 10.1091/mbc.E11-09-0784.PubMedCentralCrossRefPubMed

58.

Smrt RD, Eaves-Egenes J, Barkho BZ, Santistevan NJ, Zhao C, Aimone JB, Gage FH, Zhao X: Mecp2 deficiency leads to delayed maturation and altered gene expression in hippocampal neurons. Neurobiol Dis. 2007, 27: 77-89. 10.1016/j.nbd.2007.04.005.PubMedCentralCrossRefPubMed

59.

Bodda C, Tantra M, Mollajew R, Arunachalam JP, Laccone FA, Can K, Rosenberger A, Mironov SL, Ehrenreich H, Mannan AU: Mild Overexpression of Mecp2 in Mice Causes a Higher Susceptibility toward Seizures. Am J Pathol. 2013, 183: 195-210. 10.1016/j.ajpath.2013.03.019.CrossRefPubMed

60.

Na ES, Nelson ED, Adachi M, Autry AE, Mahgoub MA, Kavalali ET, Monteggia LM: A mouse model for MeCP2 duplication syndrome: MeCP2 overexpression impairs learning and memory and synaptic transmission. J Neurosci. 2012, 32: 3109-3117. 10.1523/JNEUROSCI.6000-11.2012.CrossRefPubMed

61.

Chiurazzi P, Pomponi MG, Willemsen R, Oostra BA, Neri G: In vitro reactivation of the FMR1 gene involved in fragile X syndrome. Hum Mol Genet. 1998, 7: 109-113. 10.1093/hmg/7.1.109.CrossRefPubMed

62.

Nguyen A, Rauch TA, Pfeifer GP, Hu VW: Global methylation profiling of lymphoblastoid cell lines reveals epigenetic contributions to autism spectrum disorders and a novel autism candidate gene, RORA, whose protein product is reduced in autistic brain. FASEB J. 2010, 24: 3036-3051. 10.1096/fj.10-154484.PubMedCentralCrossRefPubMed

63.

Im HI, Hollander JA, Bali P, Kenny PJ: MeCP2 controls BDNF expression and cocaine intake through homeostatic interactions with microRNA-212. Nat Neurosci. 2010, 13: 1120-1127. 10.1038/nn.2615.PubMedCentralCrossRefPubMed

64.

Feng J, Nestler EJ: MeCP2 and drug addiction. Nat Neurosci. 2010, 13: 1039-1041. 10.1038/nn0910-1039.CrossRefPubMed

65.

Yu D, Sakurai F, Corey DR: Clonal Rett Syndrome cell lines to test compounds for activation of wild-type MeCP2 expression. Bioorgan Med Chem Lett. 2011, 21: 5202-5205. 10.1016/j.bmcl.2011.07.053.CrossRef

66.

Mill J, Tang T, Kaminsky Z, Khare T, Yazdanpanah S, Bouchard L, Jia P, Assadzadeh A, Flanagan J, Schumacher A, Wang SC, Petronis A: Epigenomic profiling reveals DNA-methylation changes associated with major psychosis. Am J Hum Genet. 2008, 82: 696-711. 10.1016/j.ajhg.2008.01.008.PubMedCentralCrossRefPubMed

67.

Movassagh M, Choy MK, Goddard M, Bennett MR, Down TA, Foo RS: Differential DNA methylation correlates with differential expression of angiogenic factors in human heart failure. PloS one. 2010, 5: e8564-10.1371/journal.pone.0008564.PubMedCentralCrossRefPubMed

68.

Barres R, Osler ME, Yan J, Rune A, Fritz T, Caidahl K, Krook A, Zierath JR: Non-CpG methylation of the PGC-1alpha promoter through DNMT3B controls mitochondrial density. Cell Metab. 2009, 10: 189-198. 10.1016/j.cmet.2009.07.011.CrossRefPubMed

69.

Warita K, Mitsuhashi T, Ohta K, Suzuki S, Hoshi N, Miki T, Takeuchi Y: Gene expression of epigenetic regulatory factors related to primary silencing mechanism is less susceptible to lower doses of bisphenol A in embryonic hypothalamic cells. J Toxicol Sci. 2013, 38: 285-289. 10.2131/jts.38.285.CrossRefPubMed

70.

Jowaed A, Schmitt I, Kaut O, Wullner U: Methylation regulates alpha-synuclein expression and is decreased in Parkinson′’s disease patients’ brains. J Neurosci. 2010, 30: 6355-6359. 10.1523/JNEUROSCI.6119-09.2010.CrossRefPubMed

71.

Zhang X, Wu M, Xiao H, Lee MT, Levin L, Leung YK, Ho SM: Methylation of a single intronic CpG mediates expression silencing of the PMP24 gene in prostate cancer. Prostate. 2010, 70: 765-776.PubMedCentralPubMed

72.

Ball MP, Li JB, Gao Y, Lee JH, LeProust EM, Park IH, Xie B, Daley GQ, Church GM: Targeted and genome-scale strategies reveal gene-body methylation signatures in human cells. Nat Biotechnol. 2009, 27: 361-368. 10.1038/nbt.1533.PubMedCentralCrossRefPubMed

73.

Takebayashi S, Nakao M, Fujita N, Sado T, Tanaka M, Taguchi H, Okumura K: 5-Aza-2′-deoxycytidine induces histone hyperacetylation of mouse centromeric heterochromatin by a mechanism independent of DNA demethylation. Biochem Biophys Res Comm. 2001, 288: 921-926. 10.1006/bbrc.2001.5863.CrossRefPubMed

74.

Nguyen CT, Weisenberger DJ, Velicescu M, Gonzales FA, Lin JC, Liang G, Jones PA: Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2′-deoxycytidine. Cancer Res. 2002, 62: 6456-6461.PubMed

Title: Decitabine alters the expression of Mecp2 isoforms via dynamic DNA methylation at the Mecp2 regulatory elements in neural stem cells
Authors: Vichithra RB Liyanage
Robby M Zachariah
Mojgan Rastegar
Publication date: 01-12-2013
Publisher: BioMed Central
Published in: Molecular Autism / Issue 1/2013
Electronic ISSN: 2040-2392
DOI: https://doi.org/10.1186/2040-2392-4-46

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Decitabine alters the expression of Mecp2 isoforms via dynamic DNA methylation at the Mecp2 regulatory elements in neural stem cells

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2013

Enzymes in the glutamate-glutamine cycle in the anterior cingulate cortex in postmortem brain of subjects with autism

Whole-genome sequencing in an autism multiplex family

Lack of association of rare functional variants in TSC1/TSC2 genes with autism spectrum disorder

Platelets of mice heterozygous for neurobeachin, a candidate gene for autism spectrum disorder, display protein changes related to aberrant protein kinase A activity

Serum levels of soluble platelet endothelial cell adhesion molecule-1 and vascular cell adhesion molecule-1 are decreased in subjects with autism spectrum disorder

Identification of an age-dependent biomarker signature in children and adolescents with autism spectrum disorders